Antithrombotic Effect of Antisense Factor XI Oligonucleotide Treatment in Primates
Jeffrey R. Crosby(Oregon Health & Science University), Brett P. Monia(Ionis Pharmaceuticals (United States)), David Gailani(Vanderbilt University), András Gruber, Dacao Gao(Oregon Health & Science University), Anton Matafonov(Vanderbilt University), Ulla M. Marzec, Chenguang Zhao(Oregon Health & Science University), A. Robert MacLeod(Ionis Pharmaceuticals (United States)), Alexey S. Revenko(Ionis Pharmaceuticals (United States)), Stephen R. Hanson(Oregon Health & Science University), Erik I. Tucker(Oregon Health & Science University)
Cited by 128
Related Papers
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis
|Hepatology|2007|1k
Evaluation of 2‘-modified oligonucleotides containing 2‘-deoxy gaps as antisense inhibitors of gene expression
|Journal of Biological Chemistry|1993|770